CLAIMS

1. A compound of Formula (I'):



I'

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za};

each R^{Za} independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta};

each R^{Ta} independently is halogen, CN, -OH, $-NH_2$, -C(=O)OH, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, CN, -OH, $-NH_2$, $-OR^{A1a}$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1a}; and

each R^{A1a} independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{A1b}; and

each R^{A1b} independently is halogen, CN, -OH, or $-NH_2$.

2. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH or N;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Za};

each R^{Za} independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta};

each R^{Ta} independently is halogen, CN, -OH, $-NH_2$, -C(=O)OH, -O-(C_1-C_6 alkylC_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, CN, -OH, $-NH_2$, $-OR^{A1a}$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^{A1a}; and

each R^{A1a} independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^{A1b}; and

each R^{A1b} independently is halogen, CN, -OH, or $-NH_2$;

provided that when Z is , then Ar^1 is C_6-C_{10} aryl optionally substituted with one or more halogen.

3. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, or 3- to 10-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, or 3- to 10-membered heterocycloalkyl is optionally substituted with one or more halogen;

T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, -OH, -O-(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, or 3- to 7-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, -OR^{A1a}, or -O-(C_1-C_6 alkyl) optionally substituted with one or more R^{A1a}; and

each R^{A1a} independently is C_6-C_{10} aryl or 5- to 10-membered heteroaryl; wherein the C_6-C_{10} aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen.

4. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, -O-(C_1-C_6 alkyl), or C_1-C_6 alkyl; wherein the -O-(C_1-C_6 alkyl) or C_1-C_6 alkyl is optionally substituted with one or more halogen;

T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, -OH, -O-(C_1-C_6 alkyl), or 3- to 7-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, -OR^{A1a}, or -O-(C_1-C_6 alkyl) optionally substituted with one or more R^{A1a}; and

each R^{A1a} independently is C_6-C_{10} aryl or 5- to 10-membered heteroaryl; wherein the C_6-C_{10} aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen;

provided that when Z is  , then Ar^1 is C_6-C_{10} aryl optionally substituted with one or more halogen.

5. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z;

each R^Z independently is halogen, -O-(C_1-C_6 alkyl), or C_1-C_6 alkyl; wherein the -O-(C_1-C_6 alkyl) or C_1-C_6 alkyl is optionally substituted with one or more halogen;

T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, -OH, -O-(C_1-C_6 alkyl), or 3- to 7-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH;

Ar^1 is C_6-C_{10} aryl optionally substituted with one or more halogen.

6. The compound of any one of the preceding claims, wherein the compound is of Formula (I') or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

W is CH;

Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more C_1-C_6 alkyl;

T is C_2-C_6 alkenyl optionally substituted with one or more 6-membered heterocycloalkyl; and

Ar^1 is C_6 aryl optionally substituted with one or more halogen.

7. The compound of any one of the preceding claims, wherein W is CH.

8. The compound of any one of the preceding claims, wherein Z is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R^Z; and

each R^Z independently is halogen, -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, or 3- to 10-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, or 3- to 10-membered heterocycloalkyl is optionally substituted with one or more halogen.

9. The compound of any one of the preceding claims, wherein Z is oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl,3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-5-azaspiro[3.4]octanyl, wherein the oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, or 2-oxa-5-azaspiro[3.4]octanyl is optionally substituted with one or more R^Z.

10. The compound of any one of the preceding claims, wherein Z is oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-oxabicyclo[3.1.0]hexanyl,3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, 2-oxa-5-azaspiro[3.4]octanyl, wherein the oxetanyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, 3-azabicyclo[3.1.0]hexanyl, 2-azaspiro[3.3]heptanyl, or 2-oxa-5-azaspiro[3.4]octanyl is optionally substituted with one or more R^Z.

11. The compound of any one of the preceding claims, wherein Z is , , , , , , , , , , , , .



12. The compound of any one of the preceding claims, wherein Z is 





13. The compound of any one of the preceding claims, wherein at least one R^Z is halogen.

14. The compound of any one of the preceding claims, wherein at least one R^Z is F or Cl.

15. The compound of any one of the preceding claims, wherein at least one R^Z is -O-(C_1-C_6 alkyl) optionally substituted with one or more R^{Za}.

16. The compound of any one of the preceding claims, wherein at least one R^Z is -OCH_3.

17. The compound of any one of the preceding claims, wherein at least one R^Z is C_1-C_6 alkyl.

18. The compound of any one of the preceding claims, wherein at least one R^Z is methyl, ethyl, or propyl.

19. The compound of any one of the preceding claims, wherein at least one R^Z is C_1-C_6 alkyl substituted with one or more halogen.

20. The compound of any one of the preceding claims, wherein at least one R^Z is CF_3.

21. The compound of any one of the preceding claims, wherein at least one R^Z is 3- to 10-membered heterocycloalkyl optionally substituted with one or more R^{Za}.

22. The compound of any one of the preceding claims, wherein at least one R^Z is oxetanyl.

23. The compound of any one of the preceding claims, wherein T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T;

each R^T independently is halogen, CN, -OH, -NH_2, -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 7-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R^{Ta}; and

each R^{Ta} independently is halogen, CN, -OH, -NH_2, -C(=O)OH, -O-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 3- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl.

24. The compound of any one of the preceding claims, wherein T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T; and

each R^T independently is halogen, -OH, -O-(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, or 3- to 7-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.

25. The compound of any one of the preceding claims, wherein T is –O-(C_1-C_6 alkyl), –NH-(C_1-C_6 alkyl), C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^T; and

each R^T independently is halogen, -OH, -O-(C_1-C_6 alkyl), or 3- to 7-membered heterocycloalkyl; wherein the -O-(C_1-C_6 alkyl), or 3- to 7-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.

26. The compound of any one of the preceding claims, wherein T is –O-(C_1-C_6 alkyl) optionally substituted with one or more R^T.

27. The compound of any one of the preceding claims, wherein T is –NH-(C_1-C_6 alkyl) optionally substituted with one or more R^T.

28. The compound of any one of the preceding claims, wherein T is C_1-C_6 alkyl optionally substituted with one or more R^T.

29. The compound of any one of the preceding claims, wherein T is C_1-C_6 alkyl.

30. The compound of any one of the preceding claims, wherein T is C_1-C_6 alkyl substituted with one or more halogen.

31. The compound of any one of the preceding claims, wherein T is -CHFCl.

32. The compound of any one of the preceding claims, wherein T is C_2-C_6 alkenyl.

33. The compound of any one of the preceding claims, wherein T is C_2-C_6 alkenyl substituted with one or more -OH, -O-(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, or 3- to 10-membered heterocycloalkyl; wherein the 3- to 10-membered heterocycloalkyl is optionally substituted with one or more -C(=O)OH.

34. The compound of any one of the preceding claims, wherein T is C_2-C_6 alkynyl.

35. The compound of any one of the preceding claims, wherein T is propynyl.

36. The compound of any one of the preceding claims, wherein T is propynyl substituted with one or more 3- to 10-membered heterocycloalkyl .

37. The compound of any one of the preceding claims, wherein T is , .

38. The compound of any one of the preceding claims, wherein T is , .



39. The compound of any one of the preceding claims, wherein at least one R^T is halogen.

40. The compound of any one of the preceding claims, wherein at least one R^T is CN, -OH, or $-NH_2$.

41. The compound of any one of the preceding claims, wherein at least one R^T is -O-(C_1-C_6 alkyl) or -N(C_1-C_6 alkyl)$_2$.

42. The compound of any one of the preceding claims, wherein at least one R^T is 3- to 10-membered heterocycloalkyl substituted with one or more C(=O)OH.

43. The compound of any one of the preceding claims, wherein at least one R^{Ta} is C(=O)OH.

44. The compound of any one of the preceding claims, wherein Ar^1 is C_6-C_{10} aryl optionally substituted with one or more R^{A1};

each R^{A1} independently is halogen, CN, -OH, $-NH_2$, $-OR^{A1a}$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^{A1a};

each R^{A1a} independently is halogen, CN, -OH, $-NH_2$, -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl; wherein the -O-(C_1-C_6 alkyl), -NH(C_1-C_6 alkyl), -N(C_1-C_6 alkyl)$_2$, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6 alkynyl is optionally substituted with one or more R^{A1b}; and

each R^{A1b} independently is halogen, CN, -OH, or $-NH_2$.

45. The compound of any one of the preceding claims, wherein Ar^1 is C_6-C_{10} aryl substituted with one or more R^{A1}.

46. The compound of any one of the preceding claims, wherein Ar^1 is phenyl substituted with one or more halogen.

47. The compound of any one of the preceding claims, wherein Ar^1 is phenyl substituted with one F and one Cl.

48. The compound of any one of the preceding claims, wherein Ar^1 is phenyl optionally substituted with one or more halogen, wherein the phenyl is further substituted with –O-(C_6-C_{10} aryl) or –O-(5- to 10-membered heteroaryl); wherein the –O-(C_6-C_{10} aryl) or –O-(5- to 10-membered heteroaryl) is optionally substituted with one or more halogen.

49. The compound of any one of the preceding claims, wherein Ar^1 is phenyl optionally substituted with one or more halogen, wherein the phenyl is further substituted with –O-phenyl or –O-pyridinyl; wherein the –O-phenyl or –O-pyridinyl is optionally substituted with one or more halogen.

50. The compound of any one of the preceding claims, wherein Ar^1 is 

, 

, 

, 

, or 

.

51. The compound of any one of the preceding claims, wherein Ar^1 is , , or .

52. The compound of any one of the preceding claims, wherein Ar^1 is 

or .

53. The compound of any one of the preceding claims, wherein Ar^1 is .

54. The compound of any one of the preceding claims, wherein at least one R^{A1} is halogen.

55. The compound of any one of the preceding claims, wherein at least one R^{A1} is F, and at least one R^{A1} is Cl.

56. The compound of any one of the preceding claims, wherein at least one R^{A1} is –O-phenyl or –O-pyridinyl; wherein the –O-phenyl or –O-pyridinyl is optionally substituted with one or more halogen.

57. The compound of any one of the preceding claims, wherein at least one R^{A1} is -O-CH_2-phenyl or -O-CH_2-pyridinyl, wherein the -O-CH_2-phenyl or -O-CH_2-pyridinyl is optionally substituted with one or more halogen.

58. The compound of any one of the preceding claims, wherein at least one R^{A1a} is phenyl or pyridinyl; wherein the phenyl or pyridinyl is optionally substituted with one or more halogen.

59. The compound of any one of the preceding claims, wherein at least one R^{A1b} is halogen.

60. The compound of any one of the preceding claims, wherein at least one R^{A1b} is F, and at least one R^{A1b} is Cl.

61. The compound of any one of the preceding claims, wherein the compound is of formula (II'):



(II'),

or a pharmaceutically acceptable salt or stereoisomer thereof.

62. The compound of any one of the preceding claims, wherein the compound is of formula (II'):



(II'),

or a pharmaceutically acceptable salt or stereoisomer thereof.

63. The compound of any one of the preceding claims, wherein the compound is of formula (III') or (III'-a):



(III'),



(III-a'),

or a pharmaceutically acceptable salt or stereoisomer thereof.

64. The compound of any one of the preceding claims, wherein the compound is of formula (IV') or (IV'-a):



(IV'),



(IV-a'),

or a pharmaceutically acceptable salt or stereoisomer thereof.

65. The compound of any one of the preceding claims, wherein the compound is of formula I



I

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

W is CH or N;

X^1 is –O–, –S–, $–NR^3–$;

R^a, R^b are independently of each other hydrogen, C_{1-4} alkyl or one of R^a is $–(CH_2)_p–$ which forms a ring with X^1 if X^1 is NR^3 or one of R^a is $–(CH_2)_p–$ which forms a ring with R^2

R^c, R^d are independently of each other hydrogen or C_{1-4} alkyl;

R^1 is H or F;

R^2 is hydrogen or C_{1-4} alkyl, or is $–(CH_2)_q–$ which forms a ring with R^3 or with one of R^a;

R^3 is hydrogen or C_{1-4} alkyl, preferably hydrogen or methyl, or is $–(CH_2)_p–$ which forms a ring with R^2;

m is 1, 2 or 3;

n is 0, 1 or 2;

p is 1 or 2;

q is 0, 1 or 2 and

Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-CF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy-C_{1-6} alkyl, C_{1-6} alkoxy-C_6 aryl, C_{1-6} alkoxy-C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl-C_6 aryl, C_{1-6} aminoalkyl-C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl.

66. The compound of any one of the preceding claims, wherein Ar^1 is of formula i or pharmaceutically acceptable salts or stereoisomers thereof



i

wherein

R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy-C_{1-6} alkyl, C_{1-6} alkoxy-C_6 aryl, C_{1-6} alkoxy-C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl-C_6 aryl, C_{1-6} aminoalkyl-C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl;

R^5, $R^{5'}$, R^6, $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl.

67. The compound of any one of the preceding claims, wherein Ar^1 is of formula ii-1, ii-2, ii-3 or ii-4 or pharmaceutically acceptable salts or stereoisomers thereof



ii-1 ii-2 ii-3 ii-4

wherein

X^2 is O, NH or NMe;

X^3 is CH or N;

o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5, $R^{5'}$, R^6, $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

68. The compound of any one of the preceding claims, wherein Ar^1 is of formula iii-1, iii-2, iii-3 or iii-4, iii-5, iii-6 or iii-7 or pharmaceutically acceptable salts or stereoisomers thereof



iii-1 iii-2 iii-3 iii-4

iii-5 iii-6 iii-7

wherein

X^3 is CH or N, preferably N;

o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5, R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

69. The compound of any one of the preceding claims, wherein Ar^1 is of formula iv-1, iv-2, iv-3 or iv-4, iv-5, iv-6, iv-7, iv-8 or iv-9 or pharmaceutically acceptable salts or stereoisomers thereof



iv-1



iv-2



iv-3



iv-4



iv-5



iv-6



iv-7



iv-8



iv-9

wherein

o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5, $R^{5'}$, R^6, $R^{6'}$ are independently of each other hydrogen, -CF_3 or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F.

70. The compound of any one of the preceding claims, being of formula IIa or IIb



IIa



IIb

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

X^1 is –O– or –NR^3–;

R^1 is H or F;

R^2 is hydrogen or $C_{1\text{-}4}$ alkyl, preferably methyl or is –$(CH_2)_q$– which forms a ring with R^3;

R^3 is hydrogen or C_{1-4} alkyl, preferably hydrogen or methyl, or is $–(CH_2)_p–$ which forms a ring with R^2;

m is 1, 2 or 3;

n is 0, 1 or 2;

p is 1 or 2;

q is 0, 1 or 2;

r is 0 or 1;

s is 1 or 2; and

Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-CF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy-C_{1-6} alkyl, C_{1-6} alkoxy-C_6 aryl, C_{1-6} alkoxy-C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl-C_6 aryl, C_{1-6} aminoalkyl-C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, aryl C_{1-6} alkoxy, or C_6 aryl.

71. The compound of any one of the preceding claims, being of formula III



III

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;

Ar^1 is a 6-membered aryl, which is unsubstituted or substituted with one or more of a group selected from halogen, $-CF_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy-C_{1-6} alkyl, C_{1-6} alkoxy-C_6 aryl, C_{1-6} alkoxy-C_{5-6} heteroaryl, amino, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl-C_6 aryl, C_{1-6} aminoalkyl-C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl, or C_6 aryl;

Z is selected from



72. The compound of any one of the preceding claims, being of formula IV



IV

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;

R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-7} cycloalkyl, hydroxy C_{1-5} alkyl, C_{1-6} alkoxy-C_{1-6} alkyl, C_{1-6} alkoxy-C_6 aryl, C_{1-6} alkoxy-C_{5-6} heteroaryl, amino C_{1-4} alkyl, C_{1-6} alkylamino, C_{1-6} aminoalkyl-C_6 aryl, C_{1-6} aminoalkyl-C_{5-6} heteroaryl, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxyaminocarbonyl or C_6 aryl;

R^5, $R^{5'}$, R^6, $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

Z is selected from



73. The compound of any one of the preceding claims, being of formula V-1, V-2, V-3 or V-4



V-1



V-2



V-3



V-4

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;

X^2 is O, NH or NMe;

X^3 is C or N;

o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5, $R^{5'}$, R^6, $R^{6'}$ are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F;

Z is selected from



74. The compound of any one of the preceding claims, being of formula VI-1, VI-2, VI-3 or VI-4



VI-1



VI-2



VI-3



VI-4

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;

X^2 is O, NH or NMe;

X^3 is C or N;

o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5, R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F:

Z is selected from



.

75. The compound of any one of the preceding claims, being of formula VII-1, VII-2, VII-3 or VII-4, VII-5, VII-6 VII-7, VII-8 or VII-9



VII-1



VII-2



VII-3



VII-4



VII-5



VII-6



VII-7



VII-8



VII-9

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

R^1 is H or F;

o is 0 or 1;

R^4 is hydrogen or halogen, preferably F or Cl;

R^5, R^6 are independently of each other hydrogen, $-CF_3$ or halogen, preferably F or Cl;

R^7 is hydrogen or halogen, preferably F;

Z is selected from



.

76. The compound of any one of the preceding claims, being selected from the compounds described in Tables 1 and 2, pharmaceutically acceptable salts thereof, and stereoisomers thereof.

77. A composition comprising to the compound of any one of the preceding claims, and a pharmaceutically acceptable carrier.

78. Use of the compound, pharmaceutically acceptable salts thereof, and stereoisomers thereof, of any one of claims 1-76 in the manufacture of a medicament for the inhibition of~~A method of inhibiting~~ an oncogenic variant of an ErbB receptor~~, comprising administering the subject in need thereof a therapeutically effective amount of the compound of any one of the preceding claims~~.

79. Use of the compound, pharmaceutically acceptable salts thereof, and stereoisomers thereof, of any one of claims 1-76 in the manufacture of a medicament for the prevention or treatment of~~A method of preventing or treating~~ cancer~~, comprising administering the subject in need thereof a therapeutically effective amount of the compound of any one of the preceding claims~~.

~~80. The compound of any one of the preceding claims for use in the prevention or treatment of cancer.~~

~~81. The compound of any one of the preceding claims for use in the inhibition of an oncogenic variant of an ErbB receptor.~~

~~82.~~80. The use of claim 79~~method or the compound of any one of the preceding claims~~, wherein the cancer is a solid tumor.

~~83.~~81. The use of claim 79 or 80~~method or the compound of any one of the preceding claims~~, wherein the cancer is a bladder cancer, a breast cancer, a cervical cancer, a colorectal cancer, an endometrial cancer, a gastric cancer, a glioblastoma (GBM), a head and neck cancer, a lung cancer, a non-small cell lung cancer (NSCLC), or any subtype thereof.

~~84.~~82. The use of any one of claims 79-81~~method or the compound of any one of the preceding claims~~, wherein the cancer is glioblastoma (GBM) or any subtype thereof.

~~85.~~83. The use of any one of claims 79-81~~method or the compound of any one of the preceding claims~~, wherein the cancer is glioblastoma.

~~86.~~84. The use of any one of claims 79-83~~method or the compound of any one of the preceding claims~~, wherein the cancer, or a tumor or a cell thereof, expresses an oncogenic variant of an ErbB receptor.

~~87.~~85. The use of claim 78 or claim 84~~method or the compound of any one of the preceding claims~~, wherein the oncogenic variant of the ErbB receptor comprises an allosteric mutation.

~~88.~~86. The use of claim 78 or claim 84~~method or the compound of any one of the preceding claims~~, wherein the oncogenic variant of an ErbB receptor is is an allosteric variant of the ErbB receptor.

~~89.~~87. The use of any one of claims 78 or 84-86~~method or the compound of any one of the preceding claims~~, wherein the oncogenic variant or the oncogenic mutation is ~~detiected~~detectable by a Food and Drug Aministration (FDA)-approved diagnosis.

~~90.~~88. Use of the compound, pharmaceutically acceptable salts thereof, and stereoisomers thereof, of any one of claims 1-76 in the manufacture of a medicament for the prevention or treatment of~~A method of preventing or treating~~ glioblastoma~~, comprising administering the subject in need thereof a therapeutically effective amount of the compound of any one of the preceding claims~~.

~~91. The compound of any one of the preceding claimsfor use in the prevention or treatment of glioblastoma.~~

~~92.~~89. The use of any one of claims 78-88~~method or the compound of any one of the preceding claims~~, wherein the compound is selected from the compounds described in Tables 1 and 2, pharmaceutically acceptable salts thereof, and stereoisomers thereof.

~~93.~~90. The use of any one of claims 78-88~~method or the compound of any one of the preceding claims~~, wherein the compound is selected from the compounds described in Tables 1 and 2 and pharmaceutically acceptable salts thereof.

~~94.~~91. The use of any one of claims 78-88~~method or the compound of any one of the preceding claims~~, wherein the compound is selected from the compounds described in Table 1 and 2.